The Separate and Combined Effects of GIP, GLP-1, and GLP-2 on Markers of Bone Turnover in Type 2 Diabetes.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 40878791.
- Also identified by DOI 10.1210/clinem/dgaf482.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oral glucose tolerance test (OGTT) induces greater acute suppression of bone resorption than isoglycaemic IV glucose infusions (IIGI). To study the separate and combined effects of the gut-derived hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2) on postprandial bone turnover. A randomized, crossover study with 6 experimental days. Ten individuals with type 2 diabetes (T2D). Over 6 experimental days, participants underwent an OGTT and subsequently 5 IIGIs with infusions of saline, GIP, GLP-1, GLP-2, and GIP + GLP-1 + GLP-2, respectively. Changes in plasma concentrations of carboxy-terminal telopeptide of type I collagen (β-CTX-I) and procollagen type I N-terminal propeptide (PINP). β-CTX-I levels were significantly suppressed during OGTT compared to IIGI. Concomitant infusion of GIP + GLP-1 + GLP-2 during IIGI led to a suppression of β-CTX-I comparable to the suppression during the OGTT. During IIGI with infusions of GIP, GLP-1, and GIP + GLP-1 + GLP-2 we observed no reduction in PINP. By contrast, PINP levels were significantly reduced during both OGTT and IIGIs with saline and GLP-2, respectively. Our findings suggest that postprandial suppression of bone resorption in individuals with T2D is mediated by the additive effects of GIP, GLP-1, and GLP-2.
Medical subject headings
- Diabetes Mellitus, Type 2
- Gastric Inhibitory Polypeptide
- Glucagon-Like Peptide 2
- Glucagon-Like Peptide 1
- Bone Remodeling